But with Novartis failing to convince European regulators about the merits of Xiidra last year, and Allergan's ... a phase 3 trial for eye drops containing tivanisiran, in dry eye disease associat ...

The spokesperson added: “Allergan wants its patents to be enforced against infringers, (makers of generic eye drops) but in federal court, not in the IPR proceedings.” The tribe runs a large ...

Here's the story of how Allergan went from a small Los Angeles company known for making eye-drops to an Ireland-domiciled drug giant with a market value of $123 billion, and potentially 2015's ...

The move put Allergan in a spot to develop more branded drugs in areas like eye care, aesthetics, gastroenterology (dealing with the stomach and intestines), and women's health. Here's a shot of ...